NURS 6501N Exam 4 V3 | NURS 6501N
Advanced Pathophysiology | Actual Q&A
with Rationale (NURS6501N Exam 4) |
Walden University
1. A patient presents with bradykinesia, tremors at rest, and muscle rigidity. Which
neurotransmitter deficiency is primary in the pathophysiology of this condition?
A. Dopamine
B. Acetylcholine
C. Serotonin
D. GABA
Answer: A
Rationale: Parkinson’s disease is characterized by a significant loss of dopaminergic
neurons in the substantia nigra pars compacta. This loss results in a depletion of dopamine
in the basal ganglia, leading to the classic motor symptoms of the disease. The imbalance
between dopamine and acetylcholine further contributes to the clinical manifestations
observed in these patients.
2. In the development of Type 2 Diabetes Mellitus, what is the fundamental
pathophysiological mechanism regarding insulin?
A. Absolute insulin deficiency due to autoimmune destruction
,B. Excessive insulin production leading to hypoglycemia
C. Increased sensitivity of target tissues to insulin
D. Insulin resistance combined with a relative insulin deficiency
Answer: D
Rationale: Type 2 Diabetes Mellitus is primarily driven by the body’s inability to effectively
use insulin, known as insulin resistance. Initially, the pancreas compensates by producing
more insulin, but over time, beta-cell exhaustion leads to a decline in insulin secretion. This
combination of resistance and relative deficiency results in chronic hyperglycemia and
metabolic dysfunction.
3. A patient is diagnosed with Multiple Sclerosis (MS). What is the primary target of the
immune-mediated attack in this central nervous system disorder?
A. The myelin sheath of the axons
B. The motor endplate of the neuromuscular junction
C. The dopaminergic receptors in the striatum
D. The peripheral nerves in the lower extremities
Answer: A
Rationale: Multiple Sclerosis is a chronic inflammatory disease characterized by the
demyelination of the central nervous system. Autoreactive T and B cells cross the blood-
brain barrier to attack the myelin sheath, which insulates nerve fibers. This damage slows
, or blocks nerve impulses, leading to the varied neurological deficits associated with the
disease.
4. Which clinical manifestation is a hallmark sign of Graves’ disease resulting from
hyperthyroidism?
A. Weight gain and cold intolerance
B. Periorbital edema and dry skin
C. Exophthalmos (bulging eyes)
D. Bradycardia and constipation
Answer: C
Rationale: Graves’ disease is an autoimmune disorder where antibodies stimulate the TSH
receptor, leading to excessive thyroid hormone production. Exophthalmos occurs due to
inflammation and accumulation of glycosaminoglycans in the extraocular muscles and
retro-orbital fat. This specific ocular sign distinguishes Graves’ disease from other forms of
hyperthyroidism.
5. What is the primary cause of muscle weakness in patients diagnosed with Myasthenia
Gravis?
A. Demyelination of peripheral motor nerves
B. Inadequate release of acetylcholine from the presynaptic neuron
C. Autoantibody destruction of acetylcholine receptors at the neuromuscular junction
Advanced Pathophysiology | Actual Q&A
with Rationale (NURS6501N Exam 4) |
Walden University
1. A patient presents with bradykinesia, tremors at rest, and muscle rigidity. Which
neurotransmitter deficiency is primary in the pathophysiology of this condition?
A. Dopamine
B. Acetylcholine
C. Serotonin
D. GABA
Answer: A
Rationale: Parkinson’s disease is characterized by a significant loss of dopaminergic
neurons in the substantia nigra pars compacta. This loss results in a depletion of dopamine
in the basal ganglia, leading to the classic motor symptoms of the disease. The imbalance
between dopamine and acetylcholine further contributes to the clinical manifestations
observed in these patients.
2. In the development of Type 2 Diabetes Mellitus, what is the fundamental
pathophysiological mechanism regarding insulin?
A. Absolute insulin deficiency due to autoimmune destruction
,B. Excessive insulin production leading to hypoglycemia
C. Increased sensitivity of target tissues to insulin
D. Insulin resistance combined with a relative insulin deficiency
Answer: D
Rationale: Type 2 Diabetes Mellitus is primarily driven by the body’s inability to effectively
use insulin, known as insulin resistance. Initially, the pancreas compensates by producing
more insulin, but over time, beta-cell exhaustion leads to a decline in insulin secretion. This
combination of resistance and relative deficiency results in chronic hyperglycemia and
metabolic dysfunction.
3. A patient is diagnosed with Multiple Sclerosis (MS). What is the primary target of the
immune-mediated attack in this central nervous system disorder?
A. The myelin sheath of the axons
B. The motor endplate of the neuromuscular junction
C. The dopaminergic receptors in the striatum
D. The peripheral nerves in the lower extremities
Answer: A
Rationale: Multiple Sclerosis is a chronic inflammatory disease characterized by the
demyelination of the central nervous system. Autoreactive T and B cells cross the blood-
brain barrier to attack the myelin sheath, which insulates nerve fibers. This damage slows
, or blocks nerve impulses, leading to the varied neurological deficits associated with the
disease.
4. Which clinical manifestation is a hallmark sign of Graves’ disease resulting from
hyperthyroidism?
A. Weight gain and cold intolerance
B. Periorbital edema and dry skin
C. Exophthalmos (bulging eyes)
D. Bradycardia and constipation
Answer: C
Rationale: Graves’ disease is an autoimmune disorder where antibodies stimulate the TSH
receptor, leading to excessive thyroid hormone production. Exophthalmos occurs due to
inflammation and accumulation of glycosaminoglycans in the extraocular muscles and
retro-orbital fat. This specific ocular sign distinguishes Graves’ disease from other forms of
hyperthyroidism.
5. What is the primary cause of muscle weakness in patients diagnosed with Myasthenia
Gravis?
A. Demyelination of peripheral motor nerves
B. Inadequate release of acetylcholine from the presynaptic neuron
C. Autoantibody destruction of acetylcholine receptors at the neuromuscular junction
